Learn how to stay healthy during COVID-19 with our free guide — Coronavirus: A guide to staying healthy (and sane) while stuck indoors

Studies related to Cognitive Decline and Vinpocetine

[Efficacy Of Vinpotropile In The Therapy Of Initial Signs Of Cerebrovascular Pathology]

Effect Decrease
Values 1.9 points (MMSE)
Trial Design Cohort
Trial Length 1-6 months
Number of Subjects 20
Sex Both Genders
Age Range 45-64, 65+
Body Types Overweight
Notes for this study:
Used vinpotropile (Pyracetam) as oral dose for 30 days in patients aged 50-78 with beginning stages of chronic brain ischemia. The rate of cognitive decline appears to be attenuated as assessed by the MMSE rating scale, and subjective well being increased.

Full details on all 2 studies are available to Examine Plus members.

Already a member? Login now to access.